Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study;Tratamiento de la enfermedad de Alzheimer mediante terapia combinada de aféresis terapéutica y hemoféresis con albúmina e inmunoglobulina intravenosa: fundamentos y aproximación terapéutica al estudio AMBAR (Alzheimer Management By Albumin Replacement)

Neurologia

Volumn 31, Issue 7, 2016, Pages 473-481

  Boada, M ^a,b   Ramos Fernandez E ^c   Guivernau, B ^c   Munoz F J ^c   Costa, M ^d   Ortiz, A M ^d   Jorquera, J I ^d   Nunez L ^e   Torres, M ^e   Paez A ^e  

^a Fundacio ACE   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

^d Poligono Industrial Santiga   (Spain)

^e Departamento de Ensayos Clínicos y Farmacovigilancia   (Spain)

Author keywords

Albumin; Alzheimer disease; Beta amyloid peptide; Haemapheresis; Intravenous immunoglobulin; Plasmapheresis

Indexed keywords

AMYLOID BETA PROTEIN; HUMAN ALBUMIN; HUMAN IMMUNOGLOBULIN; ALBUMINOID; IMMUNOGLOBULIN; PROTEIN BINDING;

ALZHEIMER DISEASE; APHERESIS; CONTROLLED STUDY; HAEMAPHERESIS; HUMAN; INTERMETHOD COMPARISON; MULTICENTER STUDY; OXIDATIVE STRESS; PLASMA EXCHANGE; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; AGED; CHEMISTRY; ISOLATION AND PURIFICATION; METABOLISM; PLASMAPHERESIS; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALBUMINS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PLASMA EXCHANGE; PLASMAPHERESIS; PROTEIN BINDING;

EID: 84903805358     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: 10.1016/j.nrl.2014.02.003     Document Type: Short Survey

References (31)

1. 1 Ill-Raga, G., Ramos-Fernandez, E., Guix, F.X., Tajes, M., Bosch-Morato, M., Palomer, E., et al. Amyloid-beta peptide fibrils induce nitro-oxidative stress in neuronal cells. J Alzheimers Dis 22 (2010), 641–652.
2. 2 Kim, H.J., Chae, S.C., Lee, D.K., Chromy, B., Lee, S.C., Park, Y.C., et al. Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB J 17 (2003), 118–120.
3. 3 Lambert, M.P., Barlow, A.K., Chromy, B.A., Edwards, C., Freed, R., Liosatos, M., et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95 (1998), 6448–6453.
4. 4 Jellinger, K.A., Alzheimer disease and cerebrovascular pathology: An update. J Neural Transm 109 (2002), 813–836.
5. 5 Grimmer, T., Riemenschneider, M., Forstl, H., Henriksen, G., Klunk, W.E., Mathis, C.A., et al. Beta amyloid in Alzheimer's disease: Increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 65 (2009), 927–934.
6. 6 Deane, R., Wu, Z., Zlokovic, B.V., RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 35 (2004), 2628–2631.
7. 7 Anaya, F., Aféresis terapéutica y su aplicación en la clínica. JANO 66 (2004), 52–57.
8. 8 Bohrmann, B., Tjernberg, L., Kuner, P., Poli, S., Levet-Trafit, B., Naslund, J., et al. Endogenous proteins controlling amyloid beta-peptide polymerization. Possible implications for beta-amyloid formation in the central nervous system and in peripheral tissues. J Biol Chem 274 (1999), 15990–15995.
9. 9 DeMattos, R.B., Bales, K.R., Cummins, D.J., Dodart, J.C., Paul, S.M., Holtzman, D.M., Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98 (2001), 8850–8855.
10. 10 Dodel, R.C., Du, Y., Depboylu, C., Hampel, H., Frolich, L., Haag, A., et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 75 (2004), 1472–1474.
11. 11 Relkin, N.R., Szabo, P., Adamiak, B., Burgut, T., Monthe, C., Lent, R.W., et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 30 (2009), 1728–1736.
12. 12 Gong, Y., Chang, L., Viola, K.L., Lacor, P.N., Lambert, M.P., Finch, C.E., et al. Alzheimer's disease-affected brain: Presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 100 (2003), 10417–10422.
13. 13 Biere, A.L., Ostaszewski, B., Stimson, E.R., Hyman, B.T., Maggio, J.E., Selkoe, D.J., Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 271 (1996), 32916–32922.
14. 14 Kuo, Y.M., Kokjohn, T.A., Kalback, W., Luehrs, D., Galasko, D.R., Chevallier, N., et al. Amyloid-beta peptides interact with plasma proteins and erythrocytes: Implications for their quantitation in plasma. Biochem Biophys Res Commun 268 (2000), 750–756.
15. 15 DeMattos, R.B., Bales, K.R., Parsadanian, M., O'Dell, M.A., Foss, E.M., Paul, S.M., et al. Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem 81 (2002), 229–236.
16. ® in Alzheimer's disease patients. Alzheimers Dement 7 (2011), S456–S457.
17. 17 Stanyon, H.F., Viles, J.H., Human serum albumin can regulate amyloid-beta peptide fiber growth in the brain interstitium: Implications for Alzheimer disease. J Biol Chem 287 (2012), 28163–28168.
18. 18 Costa, M., Ortiz, A.M., Jorquera, J.I., Therapeutic albumin binding to remove amyloid-beta. J Alzheimers Dis 29 (2012), 159–170.
19. 19 Byun, K., Bayarsaikhan, E., Kim, D., Kim, C.Y., Mook-Jung, I., Paek, S.H., et al. Induction of neuronal death by microglial AGE-albumin: Implications for Alzheimer's disease. PLoS One, 7, 2012, e37917.
20. 20 Huang, X., Atwood, C.S., Hartshorn, M.A., Multhaup, G., Goldstein, L.E., Scarpa, R.C., et al. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38 (1999), 7609–7616.
21. 21 Coma, M., Guix, F.X., Uribesalgo, I., Espuna, G., Sole, M., Andreu, D., et al. Lack of oestrogen protection in amyloid-mediated endothelial damage due to protein nitrotyrosination. Brain 128 (2005), 1613–1621.
22. 22 Tajes, M., Guivernau, B., Ramos-Fernandez, E., Bosch-Morato, M., Palomer, E., Guix, F.X., et al. The pathophysiology of triose phosphate isomerase dysfunction in Alzheimer's disease. Histol Histopathol 28 (2013), 43–51.
23. 23 Del Toro, D., Coma, M., Uribesalgo, I., Guix, F.X., Muñoz, F.J., The amyloid beta-protein precursor and Alzheimer's disease. Therapeutic approaches. Current Medicinal Chemistry, 2005, 271–283.
24. 24 Guix, F.X., Uribesalgo, I., Coma, M., Muñoz, F.J., The physiology and pathophysiology of nitric oxide in the brain. Prog Neurobiol 76 (2005), 126–152.
25. 25 Boada, M., Ortiz, P., Anaya, F., Hernandez, I., Muñoz, J., Núñez, L., et al. Amyloid-targeted therapeutics in Alzheimer's disease: Use of human albumin in plasma exchange as a novel approach for Abeta mobilization. Drug News Perspect 22 (2009), 325–339.
26. 26 Gimenez-Roldan, S., Novillo, M.J., Navarro, E., Dobato, J.L., Gimenez-Zuccarelli, M., [Mini-mental state examination: Proposal of protocol to be used]. Rev Neurol 25 (1997), 576–583.
27. 27 Wouters, H., van Gool, W.A., Schmand, B., Lindeboom, R., Revising the ADAS-cog for a more accurate assessment of cognitive impairment. Alzheimer Dis Assoc Disord 22 (2008), 236–244.
28. 28 Biffi, R., Orsi, F., Pozzi, S., Pace, U., Bonomo, G., Monfardini, L., et al. Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: A randomized trial. Ann Oncol 20 (2009), 935–940.
29. 29 Merrer, J., De Jonghe, B., Golliot, F., Lefrant, J.Y., Raffy, B., Barre, E., et al. Complications of femoral and subclavian venous catheterization in critically ill patients: A randomized controlled trial. JAMA 286 (2001), 700–707.
30. 30 Parienti, J.J., Thirion, M., Megarbane, B., Souweine, B., Ouchikhe, A., Polito, A., et al. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: A randomized controlled trial. JAMA 299 (2008), 2413–2422.
31. 31 Timsit, J.F., Farkas, J.C., Boyer, J.M., Martin, J.B., Misset, B., Renaud, B., et al. Central vein catheter-related thrombosis in intensive care patients: Incidence, risks factors, and relationship with catheter-related sepsis. Chest 114 (1998), 207–213.